On May 7, 2025, Biogen (BIIB, Financial) experienced a significant adjustment in its price target by the analyst firm Mizuho. Despite maintaining an 'Outperform' rating, Mizuho reduced the price target for Biogen from $207.00 to $169.00 USD.
The analyst behind this move, Salim Syed from Mizuho, reported a decrease in the price target, reflecting an 18.36% reduction from the previous target. The current target stands at $169.00 USD, suggesting that while the firm still sees Biogen as an outperforming stock, expectations for its potential price have been scaled back.
Investors watching Biogen (BIIB, Financial) should note this adjustment as part of their overall assessment of the stock's future performance. Despite the lowered price target, the consistent 'Outperform' rating indicates a positive stance from Mizuho on Biogen's market prospects.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 29 analysts, the average target price for Biogen Inc (BIIB, Financial) is $169.84 with a high estimate of $260.00 and a low estimate of $115.00. The average target implies an upside of 45.39% from the current price of $116.82. More detailed estimate data can be found on the Biogen Inc (BIIB) Forecast page.
Based on the consensus recommendation from 37 brokerage firms, Biogen Inc's (BIIB, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Biogen Inc (BIIB, Financial) in one year is $209.60, suggesting a upside of 79.42% from the current price of $116.82. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Biogen Inc (BIIB) Summary page.
